Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis.

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2024-10-31 DOI:10.3390/cancers16213689

Taha Koray Sahin, Ruveyda Ayasun, Alessandro Rizzo, Deniz Can Guven

{"title":"Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis.","authors":"Taha Koray Sahin, Ruveyda Ayasun, Alessandro Rizzo, Deniz Can Guven","doi":"10.3390/cancers16213689","DOIUrl":null,"url":null,"abstract":"Background: The identification of reliable prognostic biomarkers is crucial for optimizing cancer treatment strategies, especially in the era of personalized medicine. This systematic review and meta-analysis evaluate the prognostic significance of the neutrophil-to-eosinophil ratio (NER) in various cancer types, with a focus on its association with overall survival (OS) and progression-free survival (PFS).Methods: We conducted a systematic literature search across PubMed, Scopus, and Web of Science databases for studies published up to 28 July 2024. We performed the meta-analyses with the generic inverse variance method with a random effects model and reported hazard ratios (HR) with 95% confidence intervals (CI).Results: The comprehensive literature search identified 10 studies comprising 2351 patients. Pooled analyses demonstrated that elevated pretreatment NER levels were significantly correlated with poorer OS (HR: 1.74, 95% CI: 1.28-2.36, p < 0.001) and PFS (HR: 1.53, 95% CI: 1.21-1.95, p < 0.001). Subgroup analyses confirmed a consistent adverse association between high NER and OS across various tumor types and geographic locations, although results from studies conducted in the Far East did not reach statistical significance.Conclusions: This meta-analysis demonstrates that elevated NER is associated with poorer OS and PFS in cancer patients, suggesting its potential utility as a non-invasive prognostic marker. Further validation in large, prospective studies is warranted to establish NER's role in guiding personalized treatment strategies across diverse oncologic contexts.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 21","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11545344/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16213689","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The identification of reliable prognostic biomarkers is crucial for optimizing cancer treatment strategies, especially in the era of personalized medicine. This systematic review and meta-analysis evaluate the prognostic significance of the neutrophil-to-eosinophil ratio (NER) in various cancer types, with a focus on its association with overall survival (OS) and progression-free survival (PFS).

Methods: We conducted a systematic literature search across PubMed, Scopus, and Web of Science databases for studies published up to 28 July 2024. We performed the meta-analyses with the generic inverse variance method with a random effects model and reported hazard ratios (HR) with 95% confidence intervals (CI).

Results: The comprehensive literature search identified 10 studies comprising 2351 patients. Pooled analyses demonstrated that elevated pretreatment NER levels were significantly correlated with poorer OS (HR: 1.74, 95% CI: 1.28-2.36, p < 0.001) and PFS (HR: 1.53, 95% CI: 1.21-1.95, p < 0.001). Subgroup analyses confirmed a consistent adverse association between high NER and OS across various tumor types and geographic locations, although results from studies conducted in the Far East did not reach statistical significance.

Conclusions: This meta-analysis demonstrates that elevated NER is associated with poorer OS and PFS in cancer patients, suggesting its potential utility as a non-invasive prognostic marker. Further validation in large, prospective studies is warranted to establish NER's role in guiding personalized treatment strategies across diverse oncologic contexts.

查看原文本刊更多论文

癌症中中性粒细胞与嗜酸性粒细胞比值（NER）的预后价值：系统回顾与元分析》。

背景：确定可靠的预后生物标志物对于优化癌症治疗策略至关重要，尤其是在个性化医疗时代。本系统综述和荟萃分析评估了中性粒细胞与嗜酸性粒细胞比值（NER）在各种癌症类型中的预后意义，重点关注其与总生存期（OS）和无进展生存期（PFS）的关系：我们在 PubMed、Scopus 和 Web of Science 数据库中对截至 2024 年 7 月 28 日发表的研究进行了系统的文献检索。我们采用随机效应模型的通用逆方差法进行了荟萃分析，并报告了危险比（HR）及95%置信区间（CI）：综合文献检索发现了 10 项研究，共 2351 名患者。汇总分析表明，治疗前 NER 水平升高与较差的 OS（HR：1.74，95% CI：1.28-2.36，p < 0.001）和 PFS（HR：1.53，95% CI：1.21-1.95，p < 0.001）显著相关。亚组分析证实，尽管远东地区的研究结果未达到统计学意义，但不同肿瘤类型和不同地理位置的高NER与OS之间存在一致的不良关联：这项荟萃分析表明，NER升高与癌症患者较差的OS和PFS有关，表明其作为非侵入性预后标志物的潜在作用。有必要在大型前瞻性研究中进一步验证 NER，以确定其在不同肿瘤情况下指导个性化治疗策略的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.